Evaluating advanced therapies for Rheumatoid Arthritis
Official title: Advanced Therapeutics in Rheumatoid Arthritis (RA)
Run by London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's · NCT03976245 · Data updated 2026-11-12
This study is testing whether a new type of oral medication for rheumatoid arthritis works better than a common injection treatment over two years.
Quick facts
| Phase | Phase 4 |
|---|---|
| Study type | Interventional |
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 144 (estimated) |
| Sponsor | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's Academic / other |
| Drugs / interventions | tofacitinib, methotrexate |
| Locations | 1 site (London, Ontario) |
| Status | Recruiting |
| Started | March 1, 2020 |
| Main results expected | March 2025 |
| Study ends | March 2025 |
| Registry record updated | November 29, 2024 |
| Trial ID | NCT03976245 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates include adults with active Rheumatoid Arthritis who have failed conventional therapies and meet specific clinical criteria.
✕Probably not a fit
Patients with contraindications to the study medications or those with certain serious health conditions may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This study evaluates the retention rates of two advanced therapies, Tumour Necrosis Factor inhibitors (TNFi) and Janus kinase inhibitors (JAK), in treating adults with Rheumatoid Arthritis (RA) over a two-year period. It aims to determine if JAK inhibitors, which are small molecule oral drugs, provide better retention rates compared to TNFi, which is commonly prescribed. The study also explores the integration of clinical trials into routine clinical practice using electronic medical records. Participants will be monitored for their response to these therapies and the reasons for any discontinuation.
Why it matters
Potential benefit: If successful, this study could lead to improved treatment retention and outcomes for patients with Rheumatoid Arthritis.
How similar studies have gone: Other studies have shown varying success with advanced therapies in Rheumatoid Arthritis, but this specific comparison of TNFi and JAK inhibitors is relatively novel.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * patients with RA who meet criteria for obtaining an advanced therapeutic through usual care * active RA with 5 or more swollen joints * seropositive * presence of erosions * failure of methotrexate and hydroxychloroquine and sulfasalazine * failure of Leflunomide -\> or equal to 18 years * able to provide consent * able to attend usual follow up visits Exclusion Criteria: * no contraindication to etanercept or tofacitinib * active serious infection * active Tuberculosis * multiple sclerosis * current cancer * lymphoma ever * previous use of an advanced therapeutic (biologic or JAK kinase inhibitor) * less than 18 years of age * unable to provide consent
Where it's running
-
Rheumatology Clinic, St. Joseph's Health Care
London, Ontario, Canada Recruiting
Study contacts
- Principal investigator: Janet E Pope, MD MPH — Western University, Canada
- Study coordinator: Janet E Pope, MD MPH
- Email: janet.pope@sjhc.london.on.ca
- Phone: 519 646-6000
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
GenAI-assisted RA bone erosion risk and DMARD choice
This study tests whether GenAI-based decision support can help doctors assess rheumatoid arthritis bone erosion risk and pick DMARDs for newly diagnosed inpatients.
-
Pain patterns in rheumatic diseases: see if pain works differently in patients and healthy people
This observational study tests how pain is experienced and measured in people with rheumatic diseases compared with healthy volunteers.
-
Telitacicept for difficult-to-treat rheumatoid arthritis
This study tests whether adding telitacicept to standard therapy helps adults with hard-to-treat rheumatoid arthritis see better control of their symptoms.
-
PTC844 in people with active rheumatoid arthritis
This study tests whether PTC844 is safe and how it behaves in the body compared with placebo for people with active rheumatoid arthritis.
-
First-in-human test of CND319 in healthy people and people with rheumatic diseases
This early study tests whether CND319 is safe and tolerable and whether it shows any signs of activity in healthy adults and in people with rheumatoid arthritis or Sjogren's syndrome.
-
IV sarilumab for adults with rheumatoid arthritis
This study tests IV sarilumab to see how it works and how safe it is for adults with moderately to severely active rheumatoid arthritis, with or without certain standard arthritis medicines.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.